Compare Boston Scientific Corporation (BSX) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Taskus Inc — how do they compare? Boston Scientific Corporation trades at $43.47 (market cap $66.37B), while Taskus Inc trades at $5.92 (market cap $530.70M). The key difference: Boston Scientific Corporation is far larger — about 125.1× Taskus Inc's market cap. Which is the better fit depends on your goals.
| BSX | TASK | |
|---|---|---|
Market Cap | $66.37B | $530.70M |
Sector | Health | Technology |
52-Week High | $108.14 | $18.21 |
52-Week Low | $42.63 | $4.57 |
Enterprise Value | $75.94B | $926.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
TaskUs (TASK) trades at $5.62, up 3.88% with strong valuation metrics including P/E of 4.97 and P/S of 0.43. The company reported Q1 2026 earnings miss but maintains solid fundamentals with 8.7% net margin and 26.52% ROE. Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages. Recent CFO appointment and robotaxi survey highlight growth initiatives.
The stock appears undervalued with 69% upside to consensus target of $9.50. Strong cash flow generation and improving debt-to-asset ratio (22.96% in 2025) support bullish case. Risks include competitive pressures and earnings volatility. Analyst consensus leans bullish with 55% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
